Stock OSE OSE IMMUNOTHERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News OSE Immunotherapeutics

Equities

OSE

FR0012127173

Market Closed - Euronext Paris
Other stock markets
 11:35:19 2024-04-18 am EDT 		After market 12:06:54 pm
5 EUR +2.56% Intraday chart for OSE Immunotherapeutics 5 0.00%
Apr. 17 OSE: licensing agreement with AbbVie enters into force CF
Apr. 17 OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OSE Immunotherapeutics Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
AQ
OSE: licensing agreement with AbbVie enters into force
CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie
MT
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
GL
OSE Immunotherapeutics SA's Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
CI
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...
Our Logo
Ose Immuno receives funding from Bpifrance
CF
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
GL
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
AQ
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
GL
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
BU
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
GL
OSE Immunotherapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
OSE IMMUNOTHERAPEUTICS : Degroof Petercam reiterates buy recommendation
CF
OSE Immunotherapeutics : Inside Information / Other news releases
PU
OSE Immuno: recruitment completed for UC trial
CF
OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis
BU
Ose Immunotherapeutics Sa Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis
CI
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
AQ
Transcript : OSE Immunotherapeutics SA - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OSE Stock
  4. News OSE Immunotherapeutics